Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder.
Aripiprazole is an atypical antipsychotic that has been shown to be more effective than placebo and at least as effective as haloperidol and risperidone in the treatment of schizophrenia and schizoaffective disorder. Despite having a well defined licensed dose range, the optimum dose for aripiprazole is yet to be established. Aripiprazole exhibits high affinity for dopamine D(2) receptors, with near maximal receptor occupancy at a dose of 30 mg. Even doses as low as 2 mg, thought not to be clinically effective, have produced striatal D(2) receptor occupancies exceeding 70%, higher than the accepted threshold for antipsychotic effect. In this review we examined the efficacy data from short-term studies of aripiprazole in relapsed schizophrenia or schizoaffective disorder, in order to establish a dose-response relationship for aripiprazole. Results of five fixed-dose studies suggest that the threshold for clinical effect is between 5 and 10 mg/day. In addition, the highest response rate is seen at 10 mg/day. Doses above 20 mg/day do not appear to provide any additional benefit and may be associated with a smaller change in symptom scores. In summary, the data available so far indicate that the optimum dose for aripiprazole is 10 mg/day and that doses above 20 mg/day provide no additional benefit.
Mace
Shubhra
S
Pharmacy Department, South London and Maudsley NHS Foundation Trust, Maudsley Hospital, London, SE5 8AZ, UK. shubhra.mace@slam.nhs.uk
Taylor
David
D
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000068180:Aripiprazole; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000188:drug therapy / Q000503:physiopathology; D015363:Quinolones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; D000068180:Aripiprazole
Psychiatr Serv. 2007 Jan;58(1):11
17215406
J Psychiatr Res. 2007 Dec;41(11):895-905
17631314
Neuropsychopharmacology. 2002 Aug;27(2):248-59
12093598
J Clin Psychopharmacol. 2008 Aug;28(4):392-400
18626265
J Clin Psychiatry. 2007 Jan;68(1):29-36
17284127
Am J Psychiatry. 2008 Mar;165(3):398; author reply 398-9
18316435
CNS Drugs. 2008;22(1):49-68; discussion 69-72
18072814
J Clin Psychiatry. 2006 Apr;67(4):626-37
16669728
J Psychopharmacol. 1993 Jan;7(4):392-3
22291004
J Clin Psychopharmacol. 2004 Apr;24(2):192-208
15206667
J Psychopharmacol. 2006 Jul;20(4):536-46
16401666
J Clin Psychopharmacol. 2005 Oct;25(5):463-7
16160622
CNS Spectr. 2006 Sep;11(9):691-702; quiz 719
16946694
Arch Gen Psychiatry. 1988 Jan;45(1):71-6
2892477
Nat Med. 2007 Sep;13(9):1102-7
17767166
J Clin Psychiatry. 2002 Sep;63(9):763-71
12363115
J Clin Psychiatry. 2003 Sep;64(9):1048-56
14628980
Psychol Med. 1994 May;24(2):307-16
7916157
J Clin Psychiatry. 2007 Oct;68(10):1480-91
17960961
Am J Psychiatry. 2003 Sep;160(9):1651-8
12944341
J Psychopharmacol. 2006 Jan;20(1):86-90
16174679
Synapse. 2008 Nov;62(11):804-18
18720421
Schizophr Bull. 1987;13(2):261-76
3616518
Am J Psychiatry. 2008 Aug;165(8):988-95
18381901
Int Clin Psychopharmacol. 2007 Nov;22(6):363-70
17917555
Arch Gen Psychiatry. 2003 Jul;60(7):681-90
12860772
Am J Psychiatry. 2007 Sep;164(9):1411-7
17728427
Am J Psychiatry. 2000 Apr;157(4):514-20
10739409
Eur J Pharmacol. 2008 Jan 14;578(2-3):222-7
18021764
Neuropsychopharmacology. 2008 Dec;33(13):3111-25
18418366
Br J Psychiatry. 2005 Sep;187:235-42
16135860
J Pharmacol Exp Ther. 2002 Jul;302(1):381-9
12065741